Loading organizations...
§ Private Profile · Saint-Eustache, QC, Canada
Medical device company specializing in airway clearance therapy products for patients with compromised pulmonary function.
Key people at Electromed International.
Founded in 1992 by Robert and Craig Hansen, Electromed is a publicly traded medical device company based in New Prague, Minnesota, that develops innovative airway clearance therapy products. The firm produces the SmartVest Airway Clearance System, which utilizes high-frequency chest wall oscillation technology delivered through a programmable air pulse generator, hose, and therapy garment. Operating from an ISO 13485 compliant 14,000-square-foot manufacturing facility, the organization serves patients with compromised pulmonary function and employs a network of over 300 certified respiratory therapists and nurses. Electromed went public via IPO in 2010, has historically generated over $19 million in annual sales, and recently reported $521,000 in international sales for the 2022 fiscal year. The company is currently led by Chief Executive Officer Jim Cunniff and Board Chair Lee Jones, succeeding former executives such as interim CEO James Cassidy.
Key people at Electromed International.
Electromed, Inc. (NYSE American: ELMD) is a profitable medical technology company that develops, manufactures, and markets innovative airway clearance devices, primarily the SmartVest® Airway Clearance System, using High Frequency Chest Wall Oscillation (HFCWO) technology.[1][2][3] It serves patients with compromised pulmonary function, such as those with bronchiectasis, cystic fibrosis, and neuromuscular diseases like cerebral palsy or ALS, targeting the U.S. homecare market and acute care settings including hospitals and ICUs.[1][2][3] The company solves the critical problem of mobilizing pulmonary secretions to improve respiratory function, reduce exacerbations, and enable better quality of life, supported by clinical data and strong reimbursement from payers.[2][3] With a vertically integrated model—including R&D, manufacturing in Minnesota, direct sales to physicians, and reimbursement support—Electromed reported record fiscal 2025 results and Q1 fiscal 2026 growth, building on FY2024 revenue of $48.1 million.[1][2][5][6]
Founded in 1992 in New Prague, Minnesota, Electromed emerged from the need to advance therapies for patients with impaired lung function, starting as a private entity funded through initial private sources before going public.[1][2][3] Specific individual founders are not prominently detailed in records, but the company was established by innovators focused on HFCWO airway clearance technology.[1] Key milestones include launching the SmartVest System around 2000, introducing multi-positional devices in 2007, wireless connectivity with SmartVest SQL® in 2010, the Clearway® touch-screen device in 2017, and ongoing expansions like expanded garment colors and next-gen tech by 2022 and 2024.[2] Early traction came from targeting home healthcare and acute settings, evolving into a leader with consistent double-digit organic growth, high margins, and public listing on NYSE American under ELMD.[1][2][3]
Electromed rides the expanding bronchiectasis and airway clearance market, fueled by rising awareness of non-CF bronchiectasis, aging populations, and post-COVID respiratory needs, with strong industry tailwinds like broad payer coverage.[2] Timing is ideal as HFCWO gains validation through clinical data amid growing demand for homecare devices that reduce hospital readmissions.[1][2][3] Market forces favoring it include consistent reimbursement, U.S. homecare dominance, and potential international expansion, positioning it against fragmented competitors via its integrated model and innovation history.[1][3] It influences the medtech ecosystem by advancing accessible HFCWO, supporting better patient outcomes, and demonstrating scalable profitability in a niche with high barriers like regulatory and reimbursement hurdles.[2]
Electromed's momentum—marked by record FY2025 results, Q1 FY2026 growth, and investments in next-gen tech—positions it for sustained double-digit revenue expansion amid a large, tailwind-driven market.[1][2][5][6] Upcoming trends like wireless enhancements, international sales, and bronchiectasis prevalence will shape its path, potentially boosting scale through operating leverage and new channels.[1][3] Its influence may evolve from U.S. homecare leader to global airway innovator, attracting value investors at low EV/revenue multiples while enhancing lives through better breathing.[2] This ties back to its founding mission: turning pulmonary challenges into active, fulfilling lives via relentless innovation.[3][4]
